GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Market Cap

Biohaven (Biohaven) Market Cap : $3,546.23 Mil (As of May. 01, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biohaven Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biohaven's share price for the quarter that ended in Dec. 2023 was $42.8. Biohaven's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 81.12 Mil. Therefore, Biohaven's market cap for the quarter that ended in Dec. 2023 was $3,471.75 Mil.

Biohaven's quarterly market cap increased from Jun. 2023 ($1,634.14 Mil) to Sep. 2023 ($1,778.15 Mil) and increased from Sep. 2023 ($1,778.15 Mil) to Dec. 2023 ($3,471.75 Mil).

Biohaven's annual market cap increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($946.48 Mil) and increased from Dec. 2022 ($946.48 Mil) to Dec. 2023 ($3,471.75 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biohaven's Enterprise Value for Today is $3,073.49 Mil.


Biohaven Market Cap Historical Data

The historical data trend for Biohaven's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Market Cap Chart

Biohaven Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Market Cap
- - 946.48 3,471.75

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 946.48 931.78 1,634.14 1,778.15 3,471.75

Competitive Comparison of Biohaven's Market Cap

For the Biotechnology subindustry, Biohaven's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biohaven's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven's Market Cap distribution charts can be found below:

* The bar in red indicates where Biohaven's Market Cap falls into.



Biohaven Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Biohaven's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$42.8*81.1157
=$3,471.75

Biohaven's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$42.8*81.1157
=$3,471.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven  (NYSE:BHVN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Biohaven Market Cap Related Terms

Thank you for viewing the detailed overview of Biohaven's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (Biohaven) Business Description

Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Executives
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139